{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:03:55Z","timestamp":1787504635839,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shire Development LLC"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.euroneuro.2018.05.012","type":"journal-article","created":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T10:30:46Z","timestamp":1532860246000},"page":"432-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder"],"prefix":"10.1016","volume":"29","author":[{"given":"Michael","family":"Huss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McBurnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Newcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.05.012_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116407","article-title":"Effect of treatment modality on long-term outcomes in attention-deficit\/hyperactivity disorder: a systematic review","volume":"10","author":"Arnold","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0002","first-page":"45","article-title":"Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale","volume":"85","author":"Arnsten","year":"2012","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0003","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1017\/S1092852900017107","article-title":"Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD","volume":"13","author":"Biederman","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0004","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0005","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0006","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1087054709332472","article-title":"Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD","volume":"13","author":"Faraone","year":"2010","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0007","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.clinthera.2013.09.005","article-title":"Guanfacine extended release: a novel treatment for attention-deficit\/hyperactivity disorder in children and adolescents","volume":"35","author":"Faraone","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0008","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.CHI.0000046908.27264.00","article-title":"A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children","volume":"42","author":"Hazell","year":"2003","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0009","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.euroneuro.2014.09.014","article-title":"Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, controlled, phase III trial","volume":"24","author":"Hervas","year":"2014","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","article-title":"Guanfacine extended release: a new pharmacological treatment option in Europe","volume":"36","author":"Huss","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/cap.2010.0064","article-title":"Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit\/hyperactivity disorder","volume":"21","author":"Kollins","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0012","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: I. Efficacy and tolerability outcomes","volume":"47","author":"Palumbo","year":"2008","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","article-title":"Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Sallee","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial","volume":"48","author":"Sallee","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0015","unstructured":"Shire Pharmaceuticals LTD, December 2015. Intuniv SmPC, Europe."},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","article-title":"Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex","volume":"129","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2018.05.012_bib0017","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","article-title":"A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder","volume":"54","author":"Wilens","year":"2015","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:52:16Z","timestamp":1760377936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18301275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924977X18301275"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.05.012","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Shire Development LLC and The Authors. Published by Elsevier B.V. on behalf of Elsevier B.V. and European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}]}}